eli lilly retatrutide press release 2024 2025 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly's Phase 3 data
Pay in 4 interest-free payments of $5.89 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 23 - Nov 28























01185-6/asset/37eb8274-11a1-4aa0-8bbe-c86defb8ff59/main.assets/gr3.jpg)




